Type 2 Diabetes Treatment Market Value in Asia-Pacific to Hit $10.5 Billion by 2020
The type 2 diabetes treatment market in Asia-Pacific (APAC) will rise in value from an estimated $6.5 billion in 2013 to $10.5 billion by 2020, representing a modest Compound Annual Growth Rate (CAGR) of 7.1%, according to business intelligence provider GBI Research.
The company’s latest report* states that of the four major APAC countries (China, India, Japan and Australia), China will see the fastest expansion, with a CAGR of 11.1% over the forecast period. This will be driven by an increase in the prevalent population due to urbanization, and by expected drug launches.
Arti Singh, Analyst for GBI Research, says: “The increasing diabetic population in India and China is the major reason behind the diabetes treatment market growth in the APAC region as a whole.
“While Metformin is expected to retain its dominant position in the treatment algorithm for type 2 diabetes, the anticipated launch of promising pipeline molecules, including several drugs with novel mechanisms of action, may also contribute to market expansion.”
The analyst notes that there is uncertainty in the future type 2 diabetes treatment market, as sulfonylureas are currently the favored combination drugs with metformin, and a number of promising GLP-1 agonists, SGLT inhibitors and DPP-4 inhibitors are in the pipeline.
Singh continues: “While sulfonylureas typically have a very low annual cost of therapy, the pipeline drugs are expected to have a very high cost, meaning that even a small swing in their market penetration will have a significant impact on growth.
“However, if these late-stage pipeline drugs fail to show consistently strong efficacy profiles across Phase III trials, or are found to have a slight chance of causing a serious adverse event, such as cancer, their commercial potential will be severely reduced.”
The analyst concludes that the widespread use of sulfonylureas and metformin, and the high level of competition among pipeline drugs, which could reduce the rate at which novel drugs can enter the market, will be the main barriers to market expansion over the forecast period.
Related News
-
News Eli Lilly gets ready to launch five new drugs in 2023
Eli Lilly, the American pharmaceutical company (IN, USA) are gearing up for a big year ahead, with hopes to launch five new drugs and capitalise on growing obesity and Alzheimer’s disease markets. -
News Amgen buys Horizon for $27.8 billion in bold step into the rare disease market
Amgen Inc buys pharmaceutical company Horizon Therapeutics in a multibillion-dollar deal, in hopes to capitalise on it's portfolio of drugs in the highly sort after rare disease market. -
News Pharma Supply Chain People Moves
The latest appointments and promotions across the pharmaceutical supply chain. -
News Merck to donate new Ebola vaccine to defend against outbreaks in Uganda
Pharmaceutical giant Merck has announced they will be speeding up the processing of a new vaccine against the latest strain of the Ebola virus, to be donated to a global non-profit organisation for distribution -
News CPHI Podcast Series: Driving innovation with pharmaceutical startups
The latest episode in the CPHI Podcast Series explores how startups are driving innovation by taking high-risk approaches and doing business with greater agility. -
News Greener and efficient processes: Quaternary Ammonium Salts
Quaternary Ammonium Salts play a crucial part in Organic Chemistry processes at many major industries. Discover why.
-
News Biosimilars save patients $11B annually, but barriers to adoption remain in US market
Biosimilars introduce competition into the biologics market, driving down prices and increasing patient access. -
News WHO recommends use of two monoclonal antibody treatments against Ebola
The health body recommended use of treatments by Regeneron and Ridgeback Bio
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance